Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab adjunctive therapy in osteoarthritis of the hip or knee
2014-003224-40Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hip osteoarthritis and knee osteoarthritis (OA) comparing Fulranumab adjunctive therapy with Placebo adjunctive therapy (2 arms). Primary endpoint: Number of participants with adverse events. Started Feb 2015; status: terminated.
02
Drugs
fulranumab
03
Conditions
hip osteoarthritisknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2014-003224-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003224-40.